Novel Molecule Shows Promising Anticancer Activity in Mice Models of Melanoma

Source: GEN Genetic Engineering & Biontechnology News, April 2022

Scientists at the University of California, Irvine (UCI), and the Italian Institute of Technology (IIT) have developed a new molecule, ALY101, that shows promising anticancer activity against a wide range of tumor cell types in mouse models of a common type of melanoma.

The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of Cancer,” are published in Cell Reports.

“CDC42 family GTPases (RHOJ, RHOQ, CDC42) are upregulated but rarely mutated in cancer and control both the ability of tumor cells to invade surrounding tissues and the ability of endothelial cells to vascularize tumors,” the researchers wrote. “Here, we use computer-aided drug design to discover a chemical entity (ARN22089) that has broad activity against a panel of cancer cell lines, inhibits S6 phosphorylation and MAPK activation, activates pro-inflammatory and apoptotic signaling, and blocks tumor growth and angiogenesis in 3D vascularized microtumor models (VMT) in vitro.”

READ THE ORIGINAL FULL ARTICLE